User:Jjjs123/sandbox

BioAtla LLC is a clinical stage biotechnology company which develops immuno-oncology treatments that specifically target cancerous tumors. BioAtla creates "naked monoclonal antibodies (mAbs), antibody drug conjugates, immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T cells" that either enable an immune system response to cancer or deliver cytotoxic payloads to tumor sites. Its lead technology, Conditionally Active Biologics (“CABs”), are antibodies which only bind to intended antigens in the presence of a tumor. This targeted treatment is designed to improve the safety and efficacy of biologic drug therapy. BioAtla has two drugs with IND approval which entered Phase 1/2 clinical trials in the US during 2018.

History
BioAtla was founded in 2007 by Jay Short, Carolyn Anderson Short, and Masood Tayebi. The Company is headquartered in San Diego, California, but additionally operates laboratories in Beijing, China. Since its formation, BioAtla has developed about 150 patented technologies.

Conditionally Active Biologics (CAB)
BioAtla’s Conditionally Active Biologics platform develops antibodies and other biologics that only activate under specific environmental conditions surrounding a tumor. These environmental conditions including specific temperatures, pressures, ions, and a low pH zone around the tumor, described by the Warburg effect, reflect the tumor’s unique cell metabolism (aerobic glycolysis). CABs are activated when they are in the presence of a tumor expressing the binding target and reversibly deactivated under normal tissue conditions; thereby they achieve a high Therapeutic Index score and increase the number of potential drug targets amenable to immunotherapy.

Comprehensive Integrated Antibody Optimization (CIAO!)
CIAO! is BioAtla’s platform that enables the development and manufacturing of CABs. The CIAO! platform enables quick selection of molecules which mirror both the body’s environment and the drug's target expression host.

Pipeline
BioAtla is developing CABs as Immune Checkpoint inhibitors and stimulators (CAB-Cs); CAB-CTLA4 is one of the targets. The company is also developing CAB-Antibody Drug Conjugates (ADCs), specifically CAB-ADCs that target the AXL and ROR2 receptors. BioAtla's partner F1 Oncology initiated clinical trials for CAB-CAR-T treatments of refractory, metastatic kidney cancer in China in 2018.

Partnerships
BioAtla entered a License and Operation Agreement with Pfizer in 2015. The partnership aimed at developing cancer immunotherapies using BioAtla’s CAB antibodies and Pfizer’s Antibody Drug Conjugates (ADCs). BioAtla’s antibodies would deliver toxic chemotherapies linked by Pfizer’s ADCs to tumor sites within healthy tissue, causing minimal damage to the healthy tissue.

BioAtla entered a Collaboration Agreement with F1 Oncology in 2016. The goal was to intersect BioAtla’s CAB antibodies and F1 Oncology’s research in CAR-T Cells to develop immunotherapies that would utilize the body’s own T-Cells against tumor sites.

BioAtla entered a Strategic Partnership in 2015 with Beijing Sinobioway Group Company Ltd. to develop and commercialize CABs in China, Hong Kong, Macau, and Taiwan. In 2017, the two companies expanded their collaboration with the addition of new antibody targets and a service and manufacturing agreement.

Business History
In June 2015, BioAtla received $30 million in a venture series from a China-based investor group.

In July 2015, BioAtla recieved $39 million in a venture series.

In December 2015, BioAtla and Pfizer announced a License and Operation Agreement in which BioAtla received more than $1 billion in up-front, regulatory and sales milestone payments.

In January and March 2016, BioAtla received $45 million in a venture series from Global BIO Impact Fund.

In December 2016, BioAtla received $36 million in CAB program selection payments from Beijing Sinobioway Group Company Ltd.